

Prof. Ingolf Cascorbi, M.D., Ph.D.

Curriculum vitae

Ingolf Cascorbi is Full Professor of Pharmacology at Kiel University and Director of the Institute of Experimental and Clinical Pharmacology, University Hospital Schleswig Holstein (UKSH), Campus Kiel, Germany.

He received a diploma degree in biochemistry in 1985 and a Ph.D. in 1989 from the Free University, Berlin, Germany. Additionally, he graduated in medicine in 1992 and specialized in clinical pharmacology in 1998 at the Charité Medical Center in Berlin. He received a Dr. med. (M.D.) in 1999 and achieved his habilitation in clinical pharmacology in 2000. From 2000-2004 he was Associate Professor of Pharmacology and Toxicology at the University of Greifswald. In 2004 he was appointed to the professorship at Kiel University.

Dr. Cascorbi has held many elected and appointed offices. Since 2012 he is Dean of Education of the Medical Faculty and is Vicechair of the UKSH Committee for Medicinal Products, Vicechair of the Ethics Committee and Chief Advisor of the Center of Clinical Studies.

Outside the university he is currently Member of the Off-Label Use Commission, German Ministry of Health and the Drug Commission of the German Medical Association. He serves on various editorial boards i.e. since 2012 as Associate Editor Clinical Pharmacology and Therapeutics. From 2003-2015 Dr. Cascorbi served on the executive Board of the European Association for Clinical Pharmacology and Therapeutics (EACPT), from 2007-2011 as its chairperson. Since 2019 he is Chair of the German Society for Clinical Pharmacology and Therapy and was President of the German Society for Experimental and Clinical Pharmacology and Toxicology in 2021.

Dr. Cascorbi served the first time for IUPHAR as Chair of the IUPHAR Section of Pharmacogenetics and Pharmacogenomics from 2006-2014. In 2018 he was elected as IUPHAR President.

His research interests are focused on pharmacogenomics and -epigenomics of drug metabolizing enzymes and membrane transporters, drug resistance in oncology, genetic risk factors of complex diseases, neurologic pain research. He has published more than 300 original papers, reviews and book chapters.

Accomplished work and future vision of IUPHAR

I am grateful and honored to work with a highly ambitious team of IUPHAR officers and executive board as well as with our administration office at Parthenon Management Group. In close cooperation with our member societies, IUPHAR started an intense renewal process by fully revisiting its governance structure, objectives and visions. This process was successfully accomplished by the acceptance of the new statutes in August 2021 and development of a new strategic plan. The entire process will be now fulfilled after the elections of individuals nominated by our members on the partly new and clearly defined positions on the executive board. It was important for us to have a President-elect as well to have the chairs of basic and of clinical pharmacology, NC-IUPHAR and in particular Early Career Researcher on board. What is new is also to have a responsible person to overview and further develop the governance as well as representative for resource limited countries.

Why to continue for another two years as President? It was agreed with our board and our members to implement the new governance but also and guarantee continuity of the many ongoing activities of IUPHAR. The Secretary General and I aim to lead the society in the transition time together with the new team to further deepen the cooperation and exchange with our many member societies. This exchange has already been established through town hall meetings but will be extended. A major task for the new EC will be the improved exchange between basic and clinical pharmacological committees and inclusion of early career researchers from various regions into the many activities. In particular we are interested to consolidate the future work of NC-IUPHAR and the Pharmacology Education Program together with our partners. The support and cooperation with regional activities such as Pharmacology for Africa or the Latin-American initiative and regional centers such as those for the Pharmacology of Natural Products will be permanent objectives on the agenda. Last not least exchange through virtual conferences should be established as a brand of IUPHAR in between our major events, the world conferences of pharmacology.